HSCS Stock Analysis: Buy, Sell, or Hold?
HSCS - HeartSciences Inc. Common Stock
$2.51
0.25 (11.24%)
▲
5d:
+3.46%
30d:
-5.49%
90d:
-20.69%
BUY
MODERATE Confidence
Analysis Updated: Mar 31, 2026 12:00 AM ET
Earnings: Mar 12, 2026
0d
Get Alerted When HSCS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: HSCS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: HSCS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: HSCS is currently trading at $2.51, which is considered slightly low relative to its 30-day fair value range of $2.44 to $2.76.
Technical Outlook: Technically, HSCS is showing sideways momentum. Immediate support is located at $2.15, while resistance sits at $2.77. The stock is showing strong short-term momentum, up 11.2% recently.
Market Sentiment: HSCS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $10.00 (+297.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, HSCS is showing sideways momentum. Immediate support is located at $2.15, while resistance sits at $2.77. The stock is showing strong short-term momentum, up 11.2% recently.
Market Sentiment: HSCS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $10.00 (+297.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$2.44 -
$2.76
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+11.2%)
- BULLISH: Trading 297.8% below Wall St target ($10.00)
Fair Price Analysis
30-Day Fair Range
$2.44 -
$2.76
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.15
Resistance Level
$2.77
Current Trend
Sideways
Technical data as of
Mar 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.89
Wall Street Target
$10.00
(+297.8%)
Revenue Growth (YoY)
653.8%
Share & Embed Analysis
Last updated: March 31, 2026 5:36 PM ET
Data refreshes hourly during market hours. Next update: 6:36 PM
Data refreshes hourly during market hours. Next update: 6:36 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HSCS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$102 | 61 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$86 | 53 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 52 HOLD |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$133 | 59 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 64 BUY |
